Cantor Fitzgerald Forecasts RCKT FY2026 Earnings

Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) – Stock analysts at Cantor Fitzgerald issued their FY2026 earnings per share estimates for Rocket Pharmaceuticals in a research note issued on Monday, June 9th. Cantor Fitzgerald analyst J. Schimmer expects that the biotechnology company will post earnings of ($1.66) per share for the year. Cantor Fitzgerald currently has a “Overweight” rating and a $30.00 target price on the stock. The consensus estimate for Rocket Pharmaceuticals’ current full-year earnings is ($2.83) per share.

Several other research analysts have also commented on the company. The Goldman Sachs Group lowered Rocket Pharmaceuticals from a “neutral” rating to a “sell” rating in a research report on Wednesday, May 28th. Jefferies Financial Group restated a “hold” rating on shares of Rocket Pharmaceuticals in a research note on Wednesday, May 28th. Morgan Stanley restated an “equal weight” rating and issued a $7.00 target price on shares of Rocket Pharmaceuticals in a research note on Wednesday, May 28th. TD Cowen restated a “hold” rating on shares of Rocket Pharmaceuticals in a research report on Tuesday, May 27th. Finally, BMO Capital Markets reduced their price objective on Rocket Pharmaceuticals from $30.00 to $8.00 and set an “outperform” rating for the company in a research report on Wednesday, May 28th. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating and eight have assigned a buy rating to the company’s stock. According to data from MarketBeat, Rocket Pharmaceuticals currently has a consensus rating of “Hold” and an average price target of $19.57.

Rocket Pharmaceuticals Price Performance

Shares of RCKT opened at $3.16 on Tuesday. The firm has a market cap of $337.44 million, a price-to-earnings ratio of -1.15 and a beta of 0.68. The stock has a 50 day moving average of $5.67 and a 200-day moving average of $8.93. The company has a current ratio of 6.05, a quick ratio of 6.05 and a debt-to-equity ratio of 0.06. Rocket Pharmaceuticals has a 52 week low of $2.19 and a 52 week high of $26.98.

Rocket Pharmaceuticals (NASDAQ:RCKT) last issued its quarterly earnings data on Tuesday, May 13th. The biotechnology company reported ($0.56) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.58) by $0.02. During the same period last year, the business posted ($0.66) EPS.

Insiders Place Their Bets

In other Rocket Pharmaceuticals news, CEO Gaurav Shah purchased 20,000 shares of Rocket Pharmaceuticals stock in a transaction on Thursday, April 10th. The stock was bought at an average price of $5.08 per share, for a total transaction of $101,600.00. Following the transaction, the chief executive officer now owns 792,680 shares of the company’s stock, valued at $4,026,814.40. The trade was a 2.59% increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, CFO Aaron Ondrey sold 7,489 shares of the business’s stock in a transaction on Friday, April 4th. The stock was sold at an average price of $5.29, for a total value of $39,616.81. Following the transaction, the chief financial officer now owns 129,650 shares of the company’s stock, valued at $685,848.50. This trade represents a 5.46% decrease in their position. The disclosure for this sale can be found here. 24.76% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Rocket Pharmaceuticals

Hedge funds have recently made changes to their positions in the business. Sovran Advisors LLC purchased a new stake in shares of Rocket Pharmaceuticals during the fourth quarter valued at $1,895,000. Raymond James Financial Inc. acquired a new stake in Rocket Pharmaceuticals during the 4th quarter valued at $285,000. Strategic Financial Concepts LLC acquired a new stake in Rocket Pharmaceuticals during the 4th quarter valued at $141,000. Two Sigma Investments LP raised its stake in Rocket Pharmaceuticals by 88.6% during the 4th quarter. Two Sigma Investments LP now owns 41,142 shares of the biotechnology company’s stock valued at $517,000 after purchasing an additional 19,326 shares during the period. Finally, Charles Schwab Investment Management Inc. raised its stake in Rocket Pharmaceuticals by 15.1% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 656,090 shares of the biotechnology company’s stock valued at $8,247,000 after purchasing an additional 86,276 shares during the period. Institutional investors and hedge funds own 98.39% of the company’s stock.

Rocket Pharmaceuticals Company Profile

Rocket Pharmaceuticals, Inc, together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia.